We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » UCB Gets Another Roadblock to FDA Approval of Psoriasis Drug, This Time a CRL
UCB Gets Another Roadblock to FDA Approval of Psoriasis Drug, This Time a CRL
UCB drew a Complete Response Letter (CRL) from the FDA rejecting the company’s Biologics License Application (BLA) for its investigational monoclonal antibody drug bimekizumab in adult patients with moderate-to-severe plaque psoriasis.